Antihistamine/Decongestant Cold Medicine Combinations in Children
Nasatapp (phenylpropanolamine plus brompheniramine) should not be used for a child’s common cold. (fda.gov) Cetirizine should not be combined with a multi-ingredient cold product containing an antihistamine such as brompheniramine. (fda.gov)
Phenylpropanolamine Contraindication for Safety
Phenylpropanolamine (PPA) has been associated with serious adverse events. (fda.gov) FDA has taken steps to remove phenylpropanolamine-containing drug products from the market. (fda.gov) FDA safety communications advise against use of cough-and-cold products in young children due to serious risk. (fda.gov)
Brompheniramine (First-Generation Antihistamine) Safety in Pediatrics
Brompheniramine is used in some cough-and-cold combination products. (medlineplus.gov) Nonprescription cough-and-cold combination products containing brompheniramine can cause serious side effects or death in young children. (medlineplus.gov) FDA advises against cough-and-cold products containing antihistamines or decongestants in children younger than 2 years. (fda.gov)
Cetirizine With Nasatapp (Duplicate Antihistamine Exposure)
Nasatapp already contains brompheniramine, an antihistamine. (medlineplus.gov) Adding cetirizine increases antihistamine exposure from two different antihistamine drugs. (fda.gov) FDA guidance emphasizes avoiding these combination products and following Drug Facts labeling for pediatric dosing and ingredient duplication. (fda.gov)
Recommended Symptom-Directed Cold Management
Supportive care is recommended for most uncomplicated common colds rather than multi-ingredient cough-and-cold combinations. (fda.gov)
When Antihistamines Are Considered
Antihistamines are appropriate only when symptoms are more consistent with allergic rhinitis rather than a typical viral common cold. (fda.gov)
Common Pitfalls to Avoid
Using multi-ingredient cough-and-cold products in young children is a safety risk. (fda.gov) Combining two antihistamine medicines increases the likelihood of adverse effects. (fda.gov)
Urgent Evaluation Indications
Evaluation is indicated for any child with severe symptoms, respiratory distress, lethargy, or signs of dehydration. (fda.gov)